Analysts’ Opinions Are Mixed on These Healthcare Stocks: Illumina (NASDAQ: ILMN) and T2 Biosystems (NASDAQ: TTOO)

By Austin Angelo

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Illumina (NASDAQ: ILMN) and T2 Biosystems (NASDAQ: TTOO).

Illumina (NASDAQ: ILMN)

In a report issued on November 1, Dane Leone from BTIG reiterated a Hold rating on Illumina (NASDAQ: ILMN). The company’s shares closed yesterday at $135.66, close to its 52-week low of $127.10.

According to TipRanks.com, Leone is a 5-star analyst with an average return of 6.6% and a 62.3% success rate. Leone covers the Healthcare sector, focusing on stocks such as Corvus Pharmaceuticals Inc, Quest Diagnostics Inc., and Trillium Therapeutics.

Currently, the analyst consensus on Illumina is Hold and the average price target is $150, representing a 10.6% upside.

In a report released yesterday, Canaccord Genuity also reiterated a Hold rating on the stock with a $135 price target.
T2 Biosystems (NASDAQ: TTOO)

In a report released yesterday, Karen Koski from BTIG reiterated a Sell rating on T2 Biosystems (NASDAQ: TTOO), with a price target of $4. The company’s shares closed yesterday at $5.77, close to its 52-week low of $4.92.

According to TipRanks.com, Koski is a 4-star analyst with an average return of 6.2% and a 48.0% success rate. Koski covers the Healthcare sector, focusing on stocks such as Accelerate Diagnostics, Orasure Technologies, and Foundation Medicine.

T2 Biosystems has an analyst consensus of Moderate Buy, with a price target consensus of $4.